Report Details:
15 Companies Covered
110 Pages
Drug Discovery Services Market Report Highlights
Drug Discovery Services Market reached an estimated USD 115.08 Billion in 2025 and is projected to grow from USD 122.56 Billion in 2026 to USD 216.04 Billion by 2035, registering a compound annual growth rate of 6.50% during the forecast period.
MRFR recognizes the following companies as the key players in the global drug discovery services market — Thermo Fisher Scientific INC. (US), Aragen Life Sciences Pvt. Ltd (India), Piramal Pharma Solutions (India), Curia Global, Inc. (US), Charles River Laboratories (US), Eurofins Scientific (Europe), IQVIA (US), Evotec (Germany), WuXi AppTec Co., Ltd. (China), Laboratory Corporation of America Holdings (US), Selvita (Poland), Sygnature Discovery (UK), Symeres (Netherlands), NuChem Sciences Inc (Canada), Paraza Pharma, Inc. (Canada)
The global drug discovery services market is driven by several factors, such as increasing R&D expenditure and rising drug development outsourcing. For instance, according to the World Bank, the average R&D expenditure as % of GDP globally had increased from 2.01% in 2010 to 2.63% in 2020. In addition, government initiatives such as the Horizon 2020 research funding initiative also aided in market growth. However, stringent regulatory guidelines on drug approval are among the major challenges to the market's growth.
Segment Analysis
The global drug discovery services market is segmented into drug type, types of services, therapeutic area, technology, end user, and region. The drug type segment is further segmented into small molecule drug and biologics drug. The types of services are segmented into drug metabolism and pharmacokinetics (DMPK) services, pharmaceutical services, medicinal chemistry, biological services, and medication.
The therapeutic area segment is further segmented into oncology, cardiovascular diseases, respiratory diseases, diabetes, and others. The technology segment is further segmented into high throughput screening, biochips, pharmacogenomics and pharmacogenetics, and metabolomics. the end-user segment is further segmented into pharmaceutical & biotechnology companies, research & academic institutes, and others.
Regional Analysis
The global drug discovery services market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World.
The North American region held the largest market share of 43.13 % in 2021. This is due to the presence of CROs in the US and a large number of pharma and biotech firms in the region. Additionally, in the US, Remicade, Rituximab, Enbrel, Infliximab, Etanercept, Adalimumab, Darbepoetin Alpha, and other drugs are among the most competitive biosimilar players. Furthermore, the presence of CROs in the US and a large number of pharma and biotech firms adds an advantage for increasing industry revenue. For instance, in January 2025, Charles River Laboratories (US) announced a strategic partnership with SAMDI Tech, Inc. (US). With this strategic partnership, Charles River becomes the sole partner for marketing SAMDI Tech's technology. Hence, the Technological advancements in drug discovery demand, and support the region's growth.
Europe is anticipated to witness significant growth over the forecast period owing to rapid technological advancements and increasing urbanization. In addition, rising investments by many key players in various clinical and non-clinical research activities outsourced by many CRO service providers, aiding in cost-effective product development, are expected to drive the European drug discovery services market during the forecast period.
The drug discovery services market in Asia-Pacific is being driven by a rising number of clinical trials and rising drug discoveries in the region. For instance, according to a World Health Organization (WHO) database study, over 125,000 clinical trials were reported to have been filed in the Asia-Pacific region between 2009 and 2018.
This suggests that the overall number of clinical trials in the Asian region has increased exponentially. Furthermore, new initiatives, such as the University of Queensland's Community for Open Antimicrobial Drug Discovery (CO-ADD), enable academic research groups to conduct high-throughput antimicrobial screening at no cost. This is assisting in increasing access to technology.
The rest of the world (ROW) includes Latin America, Africa, and the Middle East. In Latin America, The increase in the prevalence of diseases like Alzheimer’s, AIDS, arthritis, and other drug-resistant infectious diseases, has resulted in discovering of new bioactive compounds in the Middle East and Latin American countries. This has created a huge demand for drug discovery procedures. For instance, the University of Cape Town (UCT) and the CSIR (Council of Scientific and Industrial Research) launched South Africa's Biomedical Translational Research Initiative (BTRI) for biomedical research. Therefore, the factors mentioned above are responsible to boost the growth of the drug discovery services market in the rest of the world.
Key Findings of the Study
- Hit generation and screening accounted for 38.5% of Drug Discovery Services Market share in 2025, driven by automation-led throughput gains and combinatorial chemistry libraries.
- Pre-clinical candidate selection is forecast to expand at a 7.55% CAGR through 2035, the fastest among all process phases, as sponsors prioritize translational readiness earlier in the funnel.
- North America generated 46.8% of 2025 revenue, supported by the concentration of pharma headquarters and CRO infrastructure along the U.S. East Coast corridor.
- Asia-Pacific is forecast to register a 12.10% CAGR, with China and India capturing the bulk of capacity expansion investments.
